Lamivudine (Aurobindo Pharma Limited)
Welcome to the PulseAid listing for the Lamivudine drug offered from Aurobindo Pharma Limited. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Aurobindo Pharma Limited |
| NON-PROPRIETARY NAME: | Lamivudine |
| SUBSTANCE NAME: | LAMIVUDINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
Lamivudine HUMAN PRESCRIPTION DRUG Details:
| Item Description | Lamivudine from Aurobindo Pharma Limited |
| LABELER NAME: | Aurobindo Pharma Limited |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150(mg/1) |
| START MARKETING DATE: | 2016-11-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 65862-025_9726447d-1b11-4d3d-86e4-180bbb7800cb |
| PRODUCT NDC: | 65862-025 |
| APPLICATION NUMBER: | ANDA077464 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers:
